Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Multiple Sclerosis

  Free Subscription

Articles published in J Neurol

Retrieve available abstracts of 136 articles:
HTML format

Single Articles

    October 2021
  1. PREZIOSA P, Conti L, Rocca MA, Filippi M, et al
    Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity.
    J Neurol. 2021 Oct 7. pii: 10.1007/s00415-021-10832.
    PubMed     Abstract available

  2. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Oct 1. pii: 10.1007/s00415-021-10823.
    PubMed     Abstract available

  3. JARIUS S, Wilken D, Haas J, Ruprecht K, et al
    Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction.
    J Neurol. 2021;268:3758-3765.
    PubMed     Abstract available

    September 2021
  4. PUTHENPARAMPIL M, Perini P, Bergamaschi R, Capobianco M, et al
    Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors.
    J Neurol. 2021 Sep 27. pii: 10.1007/s00415-021-10782.
    PubMed     Abstract available

  5. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.
    J Neurol. 2021 Sep 17. pii: 10.1007/s00415-021-10803.
    PubMed     Abstract available

  6. ANDERSEN MA, Buron MD, Magyari M
    Late-onset MS is associated with an increased rate of reaching disability milestones.
    J Neurol. 2021;268:3352-3360.
    PubMed     Abstract available

    August 2021
  7. SUN J, Xie Y, Wang Q, Shen J, et al
    Genes associated with grey matter volume reduction in multiple sclerosis.
    J Neurol. 2021 Aug 29. pii: 10.1007/s00415-021-10777.
    PubMed     Abstract available

  8. BLOCK VJ, Pitsch EA, Gopal A, Zhao C, et al
    Identifying falls remotely in people with multiple sclerosis.
    J Neurol. 2021 Aug 17. pii: 10.1007/s00415-021-10743.
    PubMed     Abstract available

  9. MARGONI M, Preziosa P, Filippi M, Rocca MA, et al
    Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
    J Neurol. 2021 Aug 11. pii: 10.1007/s00415-021-10744.
    PubMed     Abstract available

  10. ALVINO B, Arianna F, Assunta B, Antonio C, et al
    Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2021 Aug 4. pii: 10.1007/s00415-021-10737.
    PubMed     Abstract available

  11. PARDO G, Coates S, Okuda DT
    Outcome measures assisting treatment optimization in multiple sclerosis.
    J Neurol. 2021 Aug 2. pii: 10.1007/s00415-021-10674.
    PubMed     Abstract available

  12. CORTESE R, Prosperini L, Stasolla A, Haggiag S, et al
    Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
    J Neurol. 2021;268:2895-2899.
    PubMed     Abstract available

  13. CILINGIR V, Batur M
    First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions.
    J Neurol. 2021;268:2858-2865.
    PubMed     Abstract available

    July 2021
  14. FERRARO D, Iaffaldano P, Guerra T, Inglese M, et al
    Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
    J Neurol. 2021 Jul 22. pii: 10.1007/s00415-021-10708.
    PubMed     Abstract available

  15. RAUMA I, Mustonen T, Seppa JM, Ukkonen M, et al
    Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
    J Neurol. 2021 Jul 13. pii: 10.1007/s00415-021-10664.
    PubMed     Abstract available

  16. NIESSEN A, Schwarz B, Urban M, Kramer S, et al
    Aseptic meningitis after glatiramer acetate.
    J Neurol. 2021;268:2589-2590.

    June 2021
  17. CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
    PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
    PubMed     Abstract available

  18. SANKARI SE, Van Essche C, van Pesch V
    Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.

  19. KOGEL AK, Gold R, Schneider R
    CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.

  20. S G, S L, C Z, A N, et al
    Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
    J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
    PubMed     Abstract available

  21. HAVLA J, Schultz Y, Zimmermann H, Hohlfeld R, et al
    First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neurol. 2021 Jun 11. pii: 10.1007/s00415-021-10648.

    May 2021
  22. JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
    Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
    J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
    PubMed     Abstract available

  23. CHEN MH, Chiaravalloti ND, DeLuca J
    Neurological update: cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
    PubMed     Abstract available

  24. ZRZAVY T, Pfitzner A, Flachenecker P, Rommer P, et al
    Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot study.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10596.
    PubMed     Abstract available

  25. HILDESHEIM FE, Benedict RHB, Zivadinov R, Dwyer MG, et al
    Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis.
    J Neurol. 2021 May 16. pii: 10.1007/s00415-021-10594.
    PubMed     Abstract available

  26. TOMMASIN S, Cocozza S, Taloni A, Gianni C, et al
    Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis.
    J Neurol. 2021 May 10. pii: 10.1007/s00415-021-10605.
    PubMed     Abstract available

  27. RUGGIERI S, Petracca M, De Giglio L, De Luca F, et al
    A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.
    J Neurol. 2021 May 3. pii: 10.1007/s00415-021-10576.
    PubMed     Abstract available

    April 2021
  28. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2021 Apr 22. pii: 10.1007/s00415-021-10559.
    PubMed     Abstract available

  29. COVEY TJ, Golan D, Doniger GM, Sergott R, et al
    Visual evoked potential latency predicts cognitive function in people with multiple sclerosis.
    J Neurol. 2021 Apr 18. pii: 10.1007/s00415-021-10561.
    PubMed     Abstract available

  30. CENTONZE D, Rocca MA, Gasperini C, Kappos L, et al
    Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
    J Neurol. 2021 Apr 12. pii: 10.1007/s00415-021-10545.
    PubMed     Abstract available

  31. NYGAARD MKE, Langeskov-Christensen M, Dalgas U, Eskildsen SF, et al
    Cortical diffusion kurtosis imaging and thalamic volume are associated with cognitive and walking performance in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10543.
    PubMed     Abstract available

    March 2021
  32. MATHEY G, Pische G, Soudant M, Pittion-Vouyovitch S, et al
    Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course.
    J Neurol. 2021 Mar 31. pii: 10.1007/s00415-021-10501.
    PubMed     Abstract available

  33. PINTER D, Kober SE, Fruhwirth V, Berger L, et al
    MRI correlates of cognitive improvement after home-based EEG neurofeedback training in patients with multiple sclerosis: a pilot study.
    J Neurol. 2021 Mar 30. pii: 10.1007/s00415-021-10530.
    PubMed     Abstract available

  34. HJAERESEN S, Sejbaek T, Axelsson M, Vinslov-Jensen H, et al
    The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis.
    J Neurol. 2021 Mar 4. pii: 10.1007/s00415-021-10489.
    PubMed     Abstract available

    February 2021
  35. BUCELLO S, Annovazzi P, Ragonese P, Altieri M, et al
    Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
    J Neurol. 2021 Feb 22. pii: 10.1007/s00415-021-10455.
    PubMed     Abstract available

  36. WALZL D, Solomon AJ, Stone J
    Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap.
    J Neurol. 2021 Feb 21. pii: 10.1007/s00415-021-10436.
    PubMed     Abstract available

  37. CAPONE F, Ferraro E, Motolese F, Di Lazzaro V, et al
    COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
    J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10446.

  38. FILIPPI M, Capra R, Centonze D, Gasperini C, et al
    Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus.
    J Neurol. 2021 Feb 20. pii: 10.1007/s00415-021-10466.

  39. JAKIMOVSKI D, Benedict RHB, Weinstock-Guttman B, Ozel O, et al
    Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?
    J Neurol. 2021 Feb 15. pii: 10.1007/s00415-021-10437.
    PubMed     Abstract available

  40. TREABA CA, Herranz E, Barletta VT, Mehndiratta A, et al
    The relevance of multiple sclerosis cortical lesions on cortical thinning and their clinical impact as assessed by 7.0-T MRI.
    J Neurol. 2021 Feb 1. pii: 10.1007/s00415-021-10400.
    PubMed     Abstract available

  41. BERGMAN J, Burman J, Bergenheim T, Svenningsson A, et al
    Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
    J Neurol. 2021;268:651-657.
    PubMed     Abstract available

    January 2021
  42. LUCCHINI M, Prosperini L, Buscarinu MC, Centonze D, et al
    Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
    J Neurol. 2021 Jan 26. pii: 10.1007/s00415-021-10412.
    PubMed     Abstract available

  43. HARES K, Kemp K, Loveless S, Rice CM, et al
    KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis.
    J Neurol. 2021 Jan 23. pii: 10.1007/s00415-020-10373.
    PubMed     Abstract available

  44. BOREMALM M, Sundstrom P, Salzer J
    Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Jan 21. pii: 10.1007/s00415-021-10399.
    PubMed     Abstract available

  45. CHISARI CG, Sgarlata E, Arena S, Toscano S, et al
    Rituximab for the treatment of multiple sclerosis: a review.
    J Neurol. 2021 Jan 8. pii: 10.1007/s00415-020-10362.
    PubMed     Abstract available

  46. KEVER A, Buyukturkoglu K, Riley CS, De Jager PL, et al
    Social support is linked to mental health, quality of life, and motor function in multiple sclerosis.
    J Neurol. 2021 Jan 3. pii: 10.1007/s00415-020-10330.
    PubMed     Abstract available

  47. GELIBTER S, Pisa M, Croese T, Dalla Costa G, et al
    Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis?
    J Neurol. 2021 Jan 3. pii: 10.1007/s00415-020-10322.
    PubMed     Abstract available

  48. ZHUO Z, Li Y, Duan Y, Cao G, et al
    Subtyping relapsing-remitting multiple sclerosis using structural MRI.
    J Neurol. 2021 Jan 2. pii: 10.1007/s00415-020-10376.
    PubMed     Abstract available

  49. WOO MS, Steins D, Haussler V, Kohsar M, et al
    Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients.
    J Neurol. 2021;268:5-7.

    December 2020
  50. NEMA E, Kalina A, Nikolai T, Vyhnalek M, et al
    Correction to: Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?
    J Neurol. 2020 Dec 30. pii: 10.1007/s00415-020-10294.

  51. NEUSS F, von Podewils F, Wang ZI, Susse M, et al
    Epileptic seizures in multiple sclerosis: prevalence, competing causes and diagnostic accuracy.
    J Neurol. 2020 Dec 15. pii: 10.1007/s00415-020-10346.
    PubMed     Abstract available

    November 2020
  52. PREZIOSA P, Rocca MA, Nozzolillo A, Moiola L, et al
    COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
    J Neurol. 2020 Nov 20. pii: 10.1007/s00415-020-10309.

    October 2020
  53. SIMONSEN CS, Flemmen HO, Broch L, Brunborg C, et al
    The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression.
    J Neurol. 2020 Oct 22. pii: 10.1007/s00415-020-10279.
    PubMed     Abstract available

  54. ZECCA C, Disanto G, Sacco R, MacLachlan S, et al
    Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study.
    J Neurol. 2020 Oct 21. pii: 10.1007/s00415-020-10170.
    PubMed     Abstract available

  55. ARNETH B
    Contributions of T cells in multiple sclerosis: what do we currently know?
    J Neurol. 2020 Oct 20. pii: 10.1007/s00415-020-10275.
    PubMed     Abstract available

  56. WILLIS MD, Robertson NP
    Multiple sclerosis: early indicators of disease and assessing future risk.
    J Neurol. 2020 Oct 8. pii: 10.1007/s00415-020-10239.

    September 2020
  57. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
    J Neurol. 2020 Sep 24. pii: 10.1007/s00415-020-10226.
    PubMed     Abstract available

  58. MONSCHEIN T, Salhofer-Polanyi S, Altmann P, Zrzavy T, et al
    Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis.
    J Neurol. 2020 Sep 14. pii: 10.1007/s00415-020-10074.
    PubMed     Abstract available

  59. LEJEUNE F, Chatton A, Laplaud DA, Le Page E, et al
    SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis.
    J Neurol. 2020 Sep 9. pii: 10.1007/s00415-020-10154.
    PubMed     Abstract available

  60. LO LMP, Taylor BV, Winzenberg T, Palmer AJ, et al
    Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis.
    J Neurol. 2020 Sep 3. pii: 10.1007/s00415-020-10194.
    PubMed     Abstract available

  61. LO LMP, Taylor BV, Winzenberg T, Palmer AJ, et al
    Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis.
    J Neurol. 2020 Sep 2. pii: 10.1007/s00415-020-10195.
    PubMed     Abstract available

  62. LO LMP, Taylor BV, Winzenberg T, Palmer AJ, et al
    Comorbidities contribute substantially to the severity of common multiple sclerosis symptoms.
    J Neurol. 2020 Sep 2. pii: 10.1007/s00415-020-10192.
    PubMed     Abstract available

    August 2020
  63. MANTERO V, Baroncini D, Balgera R, Guaschino C, et al
    Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.
    J Neurol. 2020 Aug 31. pii: 10.1007/s00415-020-10196.

  64. ZHANG J, Chen MJ, Zhao GX, Li HF, et al
    Common genetic variants in PRRC2A are associated with both neuromyelitis optica spectrum disorder and multiple sclerosis in Han Chinese population.
    J Neurol. 2020 Aug 29. pii: 10.1007/s00415-020-10184.
    PubMed     Abstract available

  65. CHIARAVALLOTI ND, Amato MP, Brichetto G, Chataway J, et al
    The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis.
    J Neurol. 2020 Aug 19. pii: 10.1007/s00415-020-10160.
    PubMed     Abstract available

  66. VICINI R, Brugger D, Abegg M, Salmen A, et al
    Differences in morphology and visual function of myelin oligodendrocyte glycoprotein antibody and multiple sclerosis associated optic neuritis.
    J Neurol. 2020 Aug 12. pii: 10.1007/s00415-020-10097.
    PubMed     Abstract available

  67. ASHTON K, Fuchs TA, Oship D, Zivadinov R, et al
    Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption.
    J Neurol. 2020 Aug 4. pii: 10.1007/s00415-020-10110.
    PubMed     Abstract available

    July 2020
  68. YUAN S, Xiong Y, Larsson SC
    An atlas on risk factors for multiple sclerosis: a Mendelian randomization study.
    J Neurol. 2020 Jul 29. pii: 10.1007/s00415-020-10119.
    PubMed     Abstract available

  69. ACHIRON A, Ben-David A, Gurevich M, Magalashvili D, et al
    Parity and disability progression in relapsing-remitting multiple sclerosis.
    J Neurol. 2020 Jul 28. pii: 10.1007/s00415-020-10093.
    PubMed     Abstract available

  70. CAPUANO R, Altieri M, Bisecco A, d'Ambrosio A, et al
    Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience?
    J Neurol. 2020 Jul 28. pii: 10.1007/s00415-020-10099.
    PubMed     Abstract available

  71. HAUER L, Perneczky J, Sellner J
    A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications.
    J Neurol. 2020 Jul 27. pii: 10.1007/s00415-020-10107.
    PubMed     Abstract available

  72. EVA N, Adam K, Tomas N, Martin V, et al
    Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?
    J Neurol. 2020 Jul 22. pii: 10.1007/s00415-020-10079.
    PubMed     Abstract available

  73. KALRON A, Menascu S, Hoffmann C, Achiron A, et al
    The importance of physical activity to preserve hippocampal volume in people with multiple sclerosis: a structural MRI study.
    J Neurol. 2020 Jul 22. pii: 10.1007/s00415-020-10085.
    PubMed     Abstract available

  74. LI V, Panicker JN, Haslam C, Chataway J, et al
    Use of a symptom-based questionnaire to screen for the presence of significant voiding dysfunction in patients with multiple sclerosis and lower urinary tract symptoms: a pilot study.
    J Neurol. 2020 Jul 16. pii: 10.1007/s00415-020-10068.
    PubMed     Abstract available

  75. MATEEN FJ, Rezaei S, Alakel N, Gazdag B, et al
    Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.
    J Neurol. 2020 Jul 7. pii: 10.1007/s00415-020-10045.
    PubMed     Abstract available

  76. DE SITTER A, Verhoeven T, Burggraaff J, Liu Y, et al
    Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort.
    J Neurol. 2020 Jul 3. pii: 10.1007/s00415-020-10023.
    PubMed     Abstract available

  77. KAMINSKY AL, Omorou AY, Soudant M, Pittion-Vouyovitch S, et al
    Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity.
    J Neurol. 2020 Jul 2. pii: 10.1007/s00415-020-10029.
    PubMed     Abstract available

  78. RICCITELLI GC, Pagani E, Meani A, Valsasina P, et al
    Cognitive impairment in benign multiple sclerosis: a multiparametric structural and functional MRI study.
    J Neurol. 2020 Jul 2. pii: 10.1007/s00415-020-10025.
    PubMed     Abstract available

    June 2020
  79. MANTERO V, Abate L, Basilico P, Balgera R, et al
    COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis.
    J Neurol. 2020 Jun 25. pii: 10.1007/s00415-020-10015.

  80. VAN FAALS NL, Dekker I, Balk LJ, Moraal B, et al
    Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance.
    J Neurol. 2020 Jun 20. pii: 10.1007/s00415-020-09991.
    PubMed     Abstract available

  81. KOLANKO M, Win Z, Patel N, Malik O, et al
    Using amyloid PET imaging to diagnose Alzheimer's disease in patients with multiple sclerosis.
    J Neurol. 2020 Jun 18. pii: 10.1007/s00415-020-09969.
    PubMed     Abstract available

  82. GRANBERG T, Moridi T, Brand JS, Neumann S, et al
    Enlarged perivascular spaces in multiple sclerosis on magnetic resonance imaging: a systematic review and meta-analysis.
    J Neurol. 2020 Jun 13. pii: 10.1007/s00415-020-09971.
    PubMed     Abstract available

  83. VANDEBERGH M, Goris A
    Smoking and multiple sclerosis risk: a Mendelian randomization study.
    J Neurol. 2020 Jun 11. pii: 10.1007/s00415-020-09980.
    PubMed     Abstract available

  84. LEHMANN AI, Rodgers S, Kamm CP, Mettler M, et al
    Factors associated with employment and expected work retention among persons with multiple sclerosis: findings of a cross-sectional citizen science study.
    J Neurol. 2020 Jun 11. pii: 10.1007/s00415-020-09973.
    PubMed     Abstract available

  85. FERRAZZANO G, Crisafulli SG, Baione V, Tartaglia M, et al
    Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.
    J Neurol. 2020 Jun 5. pii: 10.1007/s00415-020-09964.
    PubMed     Abstract available

  86. WELLER D, Filli L, Meyer C, Lorincz L, et al
    Impaired speed-dependent modulation of the gait pattern in multiple sclerosis.
    J Neurol. 2020 Jun 4. pii: 10.1007/s00415-020-09965.
    PubMed     Abstract available

  87. MAGHZI AH, Houtchens MK, Preziosa P, Ionete C, et al
    COVID-19 in teriflunomide-treated patients with multiple sclerosis.
    J Neurol. 2020 Jun 3. pii: 10.1007/s00415-020-09944.
    PubMed     Abstract available

  88. PATTI F, Zimatore GB, Brescia Morra V, Aguglia U, et al
    Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study.
    J Neurol. 2020;267:1812-1823.
    PubMed     Abstract available

  89. CAROTENUTO A, Costabile T, De Lucia M, Moccia M, et al
    Predictors of Nabiximols (Sativex((R))) discontinuation over long-term follow-up: a real-life study.
    J Neurol. 2020;267:1737-1743.
    PubMed     Abstract available

    May 2020
  90. TOMASSINI V, Sinclair A, Sawlani V, Overell J, et al
    Diagnosis and management of multiple sclerosis: MRI in clinical practice.
    J Neurol. 2020 May 29. pii: 10.1007/s00415-020-09930.
    PubMed     Abstract available

  91. ANGELINI L, Hodgkinson W, Smith C, Dodd JM, et al
    Wearable sensors can reliably quantify gait alterations associated with disability in people with progressive multiple sclerosis in a clinical setting.
    J Neurol. 2020 May 28. pii: 10.1007/s00415-020-09928.
    PubMed     Abstract available

  92. SIVAKOLUNDU DK, West KL, Zuppichini MD, Wilson A, et al
    BOLD signal within and around white matter lesions distinguishes multiple sclerosis and non-specific white matter disease: a three-dimensional approach.
    J Neurol. 2020 May 28. pii: 10.1007/s00415-020-09923.
    PubMed     Abstract available

  93. MOHN N, Saker F, Bonda V, Respondek G, et al
    Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.
    J Neurol. 2020 May 28. pii: 10.1007/s00415-020-09921.

  94. GOLD R, Radue EW, Giovannoni G, Selmaj K, et al
    Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
    J Neurol. 2020 May 25. pii: 10.1007/s00415-020-09835.
    PubMed     Abstract available

  95. WILLIAMS T, Zetterberg H, Chataway J
    Neurofilaments in progressive multiple sclerosis: a systematic review.
    J Neurol. 2020 May 23. pii: 10.1007/s00415-020-09917.
    PubMed     Abstract available

  96. MORRIS JK, Lopez-Leon S, Geissbuhler Y, Sabido M, et al
    A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project.
    J Neurol. 2020 May 22. pii: 10.1007/s00415-020-09913.
    PubMed     Abstract available

  97. TSANTES E, Curti E, Ganazzoli C, Puci F, et al
    The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary?
    J Neurol. 2020 May 12. pii: 10.1007/s00415-020-09894.
    PubMed     Abstract available

  98. KOCH MW, Mostert J, Greenfield J, Liu WQ, et al
    Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent.
    J Neurol. 2020 May 9. pii: 10.1007/s00415-020-09895.
    PubMed     Abstract available

  99. COLOMBO C, Confalonieri P, Rovaris M, La Mantia L, et al
    The IN-DEEP project "INtegrating and Deriving Evidence, Experiences, Preferences": a web information model on magnetic resonance imaging for people with multiple sclerosis.
    J Neurol. 2020 May 2. pii: 10.1007/s00415-020-09864.
    PubMed     Abstract available

    April 2020
  100. CHEN MH, Wylie GR, Sandroff BM, Dacosta-Aguayo R, et al
    Neural mechanisms underlying state mental fatigue in multiple sclerosis: a pilot study.
    J Neurol. 2020 Apr 29. pii: 10.1007/s00415-020-09853.
    PubMed     Abstract available

  101. SABIN J, Urtiaga S, Pilo B, Thuissard I, et al
    Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
    J Neurol. 2020 Apr 29. pii: 10.1007/s00415-020-09848.
    PubMed     Abstract available

  102. MATEEN FJ, Vogel AC, Kaplan TB, Hotan GC, et al
    Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial.
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09845.
    PubMed     Abstract available

  103. MISICKA E, Sept C, Briggs FBS
    Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09850.
    PubMed     Abstract available

  104. WILLIS MD, Robertson NP
    Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2.
    J Neurol. 2020 Apr 17. pii: 10.1007/s00415-020-09822.

  105. MATTIOLI F, Bellomi F, Stampatori C, Mariotto S, et al
    Longitudinal serum neurofilament light chain (sNfL) concentration relates to cognitive function in multiple sclerosis patients.
    J Neurol. 2020 Apr 15. pii: 10.1007/s00415-020-09832.
    PubMed     Abstract available

  106. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    J Neurol. 2020 Apr 3. pii: 10.1007/s00415-020-09811.
    PubMed     Abstract available

    March 2020
  107. CAROTENUTO A, Wilson H, Giordano B, Caminiti SP, et al
    Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications.
    J Neurol. 2020 Mar 26. pii: 10.1007/s00415-020-09806.
    PubMed     Abstract available

  108. SHEMA-SHIRATZKY S, Hillel I, Mirelman A, Regev K, et al
    A wearable sensor identifies alterations in community ambulation in multiple sclerosis: contributors to real-world gait quality and physical activity.
    J Neurol. 2020 Mar 12. pii: 10.1007/s00415-020-09759.
    PubMed     Abstract available

  109. MARGONI M, Franciotta S, Poggiali D, Riccardi A, et al
    Cerebellar gray matter lesions are common in pediatric multiple sclerosis at clinical onset.
    J Neurol. 2020 Mar 5. pii: 10.1007/s00415-020-09776.
    PubMed     Abstract available

  110. ZUBER P, Tsagkas C, Papadopoulou A, Gaetano L, et al
    Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results.
    J Neurol. 2020 Mar 2. pii: 10.1007/s00415-020-09768.
    PubMed     Abstract available

    February 2020
  111. HELLWIG K, Geissbuehler Y, Sabido M, Popescu C, et al
    Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    J Neurol. 2020 Feb 26. pii: 10.1007/s00415-020-09762.
    PubMed     Abstract available

  112. MAGON S, Tsagkas C, Gaetano L, Patel R, et al
    Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.
    J Neurol. 2020 Feb 10. pii: 10.1007/s00415-020-09740.
    PubMed     Abstract available

  113. SCHWEITZER F, Laurent S, Fink GR, Barnett MH, et al
    Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.
    J Neurol. 2020 Feb 8. pii: 10.1007/s00415-019-09690.
    PubMed     Abstract available

  114. KATSARI M, Kasselimis DS, Giogkaraki E, Breza M, et al
    A longitudinal study of cognitive function in multiple sclerosis: is decline inevitable?
    J Neurol. 2020 Feb 1. pii: 10.1007/s00415-020-09720.
    PubMed     Abstract available

    January 2020
  115. NESS NH, Schriefer D, Haase R, Ettle B, et al
    Correction to: Differentiating societal costs of disability worsening in multiple sclerosis.
    J Neurol. 2020 Jan 16. pii: 10.1007/s00415-019-09694.
    PubMed     Abstract available

  116. SHAH VV, McNames J, Mancini M, Carlson-Kuhta P, et al
    Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson's disease and matched controls during daily living.
    J Neurol. 2020 Jan 11. pii: 10.1007/s00415-020-09696.
    PubMed     Abstract available

  117. FREEDMAN MS, Brod S, Singer BA, Cohen BA, et al
    Clinical and MRI efficacy of sc IFN beta-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
    J Neurol. 2020;267:64-75.
    PubMed     Abstract available

    December 2019
  118. NESS NH, Schriefer D, Haase R, Ettle B, et al
    Differentiating societal costs of disability worsening in multiple sclerosis.
    J Neurol. 2019 Dec 17. pii: 10.1007/s00415-019-09676.
    PubMed     Abstract available

  119. HEDSTROM AK, Olsson T, Kockum I, Hillert J, et al
    Low sun exposure increases multiple sclerosis risk both directly and indirectly.
    J Neurol. 2019 Dec 17. pii: 10.1007/s00415-019-09677.
    PubMed     Abstract available

  120. DAVDA N, Tallantyre E, Robertson NP
    Early MRI predictors of prognosis in multiple sclerosis.
    J Neurol. 2019;266:3171-3173.

    November 2019
  121. LIN WS, Wang HP, Chen HM, Lin JW, et al
    Epidemiology of pediatric multiple sclerosis, neuromyelitis optica, and optic neuritis in Taiwan.
    J Neurol. 2019 Nov 28. pii: 10.1007/s00415-019-09647.
    PubMed     Abstract available

  122. TAVAZZI E, Bergsland N, Kuhle J, Jakimovski D, et al
    A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
    J Neurol. 2019 Nov 25. pii: 10.1007/s00415-019-09643.
    PubMed     Abstract available

  123. SIERRA MORALES F, Koralnik IJ, Gautam S, Samaan S, et al
    Correction to: Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    J Neurol. 2019 Nov 23. pii: 10.1007/s00415-019-09626.
    PubMed     Abstract available

  124. PROSPERINI L, Cortese A, Lucchini M, Boffa L, et al
    Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study.
    J Neurol. 2019 Nov 13. pii: 10.1007/s00415-019-09625.
    PubMed     Abstract available

  125. LECLER A, Bouzad C, Deschamps R, Maizeroi F, et al
    Optimizing 3D FLAIR to detect MS lesions: pushing past factory settings for precise results.
    J Neurol. 2019;266:2786-2795.
    PubMed     Abstract available

    October 2019
  126. MIRAFZAL S, Goujon A, Deschamps R, Zuber K, et al
    3D PSIR MRI at 3 Tesla improves detection of spinal cord lesions in multiple sclerosis.
    J Neurol. 2019 Oct 26. pii: 10.1007/s00415-019-09591.
    PubMed     Abstract available

  127. FUJIMORI J, Fujihara K, Ogawa R, Baba T, et al
    Patterns of regional brain volume loss in multiple sclerosis: a cluster analysis.
    J Neurol. 2019 Oct 25. pii: 10.1007/s00415-019-09595.
    PubMed     Abstract available

  128. SINNECKER T, Ruberte E, Schadelin S, Canova V, et al
    New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.
    J Neurol. 2019 Oct 14. pii: 10.1007/s00415-019-09565.
    PubMed     Abstract available

  129. KAMM CP, Barin L, Gobbi C, Pot C, et al
    Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.
    J Neurol. 2019 Oct 8. pii: 10.1007/s00415-019-09563.
    PubMed     Abstract available

  130. ROMEO MAL, Garassino MC, Moiola L, Galli G, et al
    Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
    J Neurol. 2019 Oct 4. pii: 10.1007/s00415-019-09562.

  131. MORALES FS, Koralnik IJ, Gautam S, Samaan S, et al
    Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    J Neurol. 2019 Oct 3. pii: 10.1007/s00415-019-09557.
    PubMed     Abstract available

    September 2019
  132. MARGONI M, Rinaldi F, Riccardi A, Franciotta S, et al
    No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab.
    J Neurol. 2019 Sep 27. pii: 10.1007/s00415-019-09554.
    PubMed     Abstract available

  133. CHOUTEAU R, Combes B, Bannier E, Snoussi H, et al
    Joint assessment of brain and spinal cord motor tract damage in patients with early RRMS: predominant impact of spinal cord lesions on motor function.
    J Neurol. 2019;266:2294-2303.
    PubMed     Abstract available

    July 2019
  134. AYRIGNAC X, Rigau V, Lhermitte B, Vincent T, et al
    Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions.
    J Neurol. 2019;266:1743-1755.
    PubMed     Abstract available

    June 2019
  135. FRAU J, Sacca F, Signori A, Baroncini D, et al
    Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    J Neurol. 2019 Jun 17. pii: 10.1007/s00415-019-09424.
    PubMed     Abstract available

    April 2019
  136. PUST GEA, Pottgen J, Randerath J, Lau S, et al
    In search of distinct MS-related fatigue subtypes: results from a multi-cohort analysis in 1.403 MS patients.
    J Neurol. 2019 Apr 19. pii: 10.1007/s00415-019-09311.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.